Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus ; day:25 ; month:4 ; year:2016 ; pages:1-12
Diabetes therapy ; (25.4.2016), 1-12
- Creator
-
Katsuno, Tomoyuki
- Contributor
-
Ikeda, Hiroki
Namba, Mitsuyoshi
SpringerLink (Online service)
- DOI
-
10.1007/s13300-016-0170-2
- URN
-
urn:nbn:de:1111-201604262152
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Katsuno, Tomoyuki
- Ikeda, Hiroki
- Namba, Mitsuyoshi
- SpringerLink (Online service)
Other Objects (12)
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial
Effekte des DPP-IV Inhibitors Sitagliptin auf die Ausdehnung und Stabilität arteriosklerotischer Läsionen in Apolipoprotein E defizienten Mäusen
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
"DPP' 94"
Synthesis of (S)-Sitagliptin
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial
Effekte des DPP-IV Inhibitors Sitagliptin auf die Ausdehnung und Stabilität arteriosklerotischer Läsionen in Apolipoprotein E defizienten Mäusen
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
"DPP' 94"
Synthesis of (S)-Sitagliptin
Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Untersuchung der Effekte des DPP-4 Inhibitors Sitagliptin auf eine Diät induzierte NASH im Mausmodell
Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes
The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial
Effekte des DPP-IV Inhibitors Sitagliptin auf die Ausdehnung und Stabilität arteriosklerotischer Läsionen in Apolipoprotein E defizienten Mäusen
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
"DPP' 94"